Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 157

1.

Novel CaM-binding motif in its NudT9H domain contributes to temperature sensitivity of TRPM2.

Gattkowski E, Johnsen A, Bauche A, Möckl F, Kulow F, Garcia Alai M, Rutherford TJ, Fliegert R, Tidow H.

Biochim Biophys Acta Mol Cell Res. 2018 Dec 22. pii: S0167-4889(18)30540-8. doi: 10.1016/j.bbamcr.2018.12.010. [Epub ahead of print]

PMID:
30584900
2.

Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma.

Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE.

Reprod Sci. 2018 Jan 1:1933719118778801. doi: 10.1177/1933719118778801. [Epub ahead of print]

PMID:
29843577
3.

MicroRNA signatures discriminate between uterine and ovarian serous carcinomas.

Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES.

Hum Pathol. 2018 Jun;76:133-140. doi: 10.1016/j.humpath.2018.02.019. Epub 2018 Mar 5.

PMID:
29518404
4.

Constitutive scaffolding of multiple Wnt enhanceosome components by Legless/BCL9.

van Tienen LM, Mieszczanek J, Fiedler M, Rutherford TJ, Bienz M.

Elife. 2017 Mar 15;6. pii: e20882. doi: 10.7554/eLife.20882. Erratum in: Elife. 2017 Mar 30;6:.

5.

Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.

Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L.

Gynecol Oncol. 2017 Apr;145(1):122-129. doi: 10.1016/j.ygyno.2017.02.008. Epub 2017 Feb 10.

6.

Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G.

Gynecol Oncol. 2017 Mar;144(3):459-467. doi: 10.1016/j.ygyno.2016.11.033. Epub 2017 Jan 13.

7.

Essential role of the Dishevelled DEP domain in a Wnt-dependent human-cell-based complementation assay.

Gammons MV, Rutherford TJ, Steinhart Z, Angers S, Bienz M.

J Cell Sci. 2016 Oct 15;129(20):3892-3902.

8.

Wnt Signalosome Assembly by DEP Domain Swapping of Dishevelled.

Gammons MV, Renko M, Johnson CM, Rutherford TJ, Bienz M.

Mol Cell. 2016 Oct 6;64(1):92-104. doi: 10.1016/j.molcel.2016.08.026. Epub 2016 Sep 29.

9.

Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.

Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE.

Eur J Gynaecol Oncol. 2016;37(2):199-203.

PMID:
27172745
10.

Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines.

Ishiguro K, Zhu YL, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES.

J Transl Sci. 2016;2(2):117-124. Epub 2016 Mar 5.

11.

Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere.

Wilcken R, Zimmermann MO, Bauer MR, Rutherford TJ, Fersht AR, Joerger AC, Boeckler FM.

ACS Chem Biol. 2015 Dec 18;10(12):2725-32. doi: 10.1021/acschembio.5b00515. Epub 2015 Oct 1.

12.

An ancient Pygo-dependent Wnt enhanceosome integrated by Chip/LDB-SSDP.

Fiedler M, Graeb M, Mieszczanek J, Rutherford TJ, Johnson CM, Bienz M.

Elife. 2015 Aug 27;4. doi: 10.7554/eLife.09073.

13.

Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics.

Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ.

Gynecol Obstet Invest. 2015 Jun 6. [Epub ahead of print]

PMID:
26067608
14.

Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer.

Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.

Int J Cancer. 2015 Dec 1;137(11):2618-29. doi: 10.1002/ijc.29632. Epub 2015 Aug 18.

15.

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.

Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM.

Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24.

16.

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.

Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD.

Gynecol Oncol. 2015 Jun;137(3):392-400. doi: 10.1016/j.ygyno.2015.03.008. Epub 2015 Mar 17. Review.

PMID:
25792179
17.

A series of malignant ovarian cancers arising from within a mature cystic teratoma: a single institution experience.

Black JD, Roque DM, Pasternak MC, Buza N, Rutherford TJ, Schwartz PE, McCarthy S, Ratner E.

Int J Gynecol Cancer. 2015 Jun;25(5):792-7. doi: 10.1097/IGC.0000000000000431.

PMID:
25790042
18.

Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis.

Joo WD, Schwartz PE, Rutherford TJ, Seong SJ, Ku J, Park H, Jung SG, Choi MC, Lee C.

Ann Surg Oncol. 2015 Oct;22(11):3695-700. doi: 10.1245/s10434-015-4443-1. Epub 2015 Feb 18. Review.

PMID:
25691282
19.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.

Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Tumour Biol. 2015 Jul;36(7):5505-13. doi: 10.1007/s13277-015-3218-4. Epub 2015 Feb 11.

20.

Frailty, cognitive impairment, and functional disability in older women with female pelvic floor dysfunction.

Erekson EA, Fried TR, Martin DK, Rutherford TJ, Strohbehn K, Bynum JP.

Int Urogynecol J. 2015 Jun;26(6):823-30. doi: 10.1007/s00192-014-2596-2. Epub 2014 Dec 17.

Supplemental Content

Loading ...
Support Center